Celastrol: The new dawn in the treatment of vascular remodeling diseases - 13/01/23
Abstract |
Evidence is mounting that abnormal vascular remodeling leads to many cardiovascular diseases (CVDs). This suggests that vascular remodeling can be a crucial target for the prevention and treatment of CVDs. Recently, celastrol, an active ingredient of the broadly used Chinese herb Tripterygium wilfordii Hook F, has attracted extensive interest for its proven potential to improve vascular remodeling. Substantial evidence has shown that celastrol improves vascular remodeling by ameliorating inflammation, hyperproliferation, and migration of vascular smooth muscle cells, vascular calcification, endothelial dysfunction, extracellular matrix remodeling, and angiogenesis. Moreover, numerous reports have proven the positive effects of celastrol and its therapeutic promise in treating vascular remodeling diseases such as hypertension, atherosclerosis, and pulmonary artery hypertension. The present review summarizes and discusses the molecular mechanism of celastrol regulating vascular remodeling and provides preclinical proof for future clinical applications of celastrol.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Celastrol is a natural pentacyclic triterpene compound with various beneficial biological activities. |
• | Inhibition of vascular inflammation, abnormal proliferation and migration of VSMCs, vascular calcification, EndMT, ECM remodeling and angiogenesis are the main mechanisms of celastrol in improving vascular remodeling. |
• | Celastrol was identified as a potential drug for vascular remodeling diseases. |
Abbreviations : VSMCs, ECM, CVDs, MMP, PDGF, IL-6, ECs, TNF-α, PAH, IL-1β, GSH, ROS, NO, Ang-II, HO-1, CAM-1, HUVECs, IFN-γ, PASMCs, CyPA, BMP2, NOX2, CKD, Nrf2, Keap1, PP2A, GSK3β, MMP-9, MMP-2, MAPK, PI3K, Akt, VEGF, HIF-1α, iNOS, ADP, VWF, AAA, L-NAME, BM, eNOS, EndMT, TGF-β, LDL, LXRα, ABCA1, LOX-1, oxLDL, MCT, IPF, EMT, STAT3, HSF-1, HSP-90, HMGB1, Gas6, IL1R1
Keywords : Celastrol, Vascular remodeling, Vascular smooth muscle cells, Endothelial dysfunction, Cardiovascular diseases
Plan
Vol 158
Article 114177- février 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?